Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial
Manish K Jha, Abu Minhajuddin, Bharathi S Gadad, Tracy Greer, Bruce Grannemann, Abigail Soyombo, Taryn L Mayes, A John Rush, Madhukar H Trivedi, Manish K Jha, Abu Minhajuddin, Bharathi S Gadad, Tracy Greer, Bruce Grannemann, Abigail Soyombo, Taryn L Mayes, A John Rush, Madhukar H Trivedi
Abstract
Objective: Currently, no valid measures inform treatment selection for depressed patients. Whether C-reactive protein (CRP) in particular and two other acute phase reactants (inflammatory markers) could differentiate between patients responding to either of two treatments with different mechanisms of action was assessed.
Method: Subjects included Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants randomly assigned to either escitalopram plus placebo (SSRI monotherapy, n=51) or bupropion plus escitalopram combination (bupropion-SSRI combination, n=55) with baseline plasma samples. CRP, serum amyloid P component, and alpha-2-macroglobulin were measured using the Bioplex Pro™ human acute-phase 4-plex panel. We conducted mixed model analyses of depressive symptom (Quick Inventory of Depressive Symptomatology Self-Report) and side-effect burden (Frequency, Intensity, and Burden of Side-Effects Rating Scale) obtained weekly or every other week over the 12-week acute-phase of CO-MED trial to evaluate the relationship between these outcomes and baseline CRP and other acute-phase reactants.
Results: The treatment arms did not differ in depressive symptom or side effect outcomes. Most participants (69.8%, 74/106) had baseline CRP levels greater than 1mg/L (indicative of systemic inflammatory activity). Higher baseline CRP levels were associated lower depression severity (correlation coefficient=-0.63) with bupropion-SSRI combination but not with SSRI monotherapy (correlation coefficient=0.40). The overall remission rate was 41.5%. The estimated remission rate with CRP threshold based assignment (SSRI monotherapy for <1mg/L and Bupropion-SSRI for ≥1mg/L) was 53.1%, with a number needed to treat of 8.6. Side effect burden was unrelated to any baseline inflammatory marker.
Conclusions: Baseline CRP levels relate differentially to antidepressant treatment outcomes in persons with major depressive disorder. Clinicaltrials.gov identifier: NCT00590863.
Keywords: Antidepressant response; Biomarker; C-reactive protein; Depression; Inflammation.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Figures
![Figure 1.. Association of Baseline C-Reactive Protein…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6080717/bin/nihms-850658-f0001.jpg)
![Figure 2.. Differential changes in depression severity…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6080717/bin/nihms-850658-f0002.jpg)
Figure 3.. Early reduction in depression severity…
Figure 3.. Early reduction in depression severity with SSRI monotherapy in depressed patients with low…
Figure 4.. Remission rates during acute-phase of…
Figure 4.. Remission rates during acute-phase of CO-MED trial based on C-reactive protein (CRP) level…
- Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.Jha MK, Minhajuddin A, Gadad BS, Greer TL, Mayes TL, Trivedi MH. Jha MK, et al. Brain Behav Immun. 2017 Nov;66:103-110. doi: 10.1016/j.bbi.2017.07.005. Epub 2017 Jul 8. Brain Behav Immun. 2017. PMID: 28698115 Free PMC article.
- The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ; CO-MED Study Team. Sung SC, et al. J Clin Psychiatry. 2012 Jul;73(7):967-76. doi: 10.4088/JCP.11m07043. Epub 2012 May 29. J Clin Psychiatry. 2012. PMID: 22687487 Clinical Trial.
- Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.Friedman ES, Davis LL, Zisook S, Wisniewski SR, Trivedi MH, Fava M, Rush AJ; CO-MED Study Team. Friedman ES, et al. Eur Neuropsychopharmacol. 2012 Mar;22(3):183-99. doi: 10.1016/j.euroneuro.2011.07.010. Epub 2011 Sep 14. Eur Neuropsychopharmacol. 2012. PMID: 21920711 Free PMC article. Clinical Trial.
- Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, Nierenberg AA, Fava M, Luther JF, Morris DW, Trivedi MH. Zisook S, et al. J Clin Psychiatry. 2011 Oct;72(10):1322-32. doi: 10.4088/JCP.10m06724. J Clin Psychiatry. 2011. PMID: 22075098 Clinical Trial.
- Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.Jha MK, Wakhlu S, Dronamraju N, Minhajuddin A, Greer TL, Trivedi MH. Jha MK, et al. J Affect Disord. 2018 Jul;234:34-37. doi: 10.1016/j.jad.2018.02.089. Epub 2018 Feb 27. J Affect Disord. 2018. PMID: 29522941 Free PMC article. Clinical Trial.
- Increased Inflammation and Treatment of Depression: From Resistance to Reuse, Repurposing, and Redesign.Felger JC. Felger JC. Adv Neurobiol. 2023;30:387-416. doi: 10.1007/978-3-031-21054-9_16. Adv Neurobiol. 2023. PMID: 36928859
- Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics.Carreon RL, Rivas-Grajales AM, Murphy N, Mathew SJ, Jha MK. Carreon RL, et al. Adv Neurobiol. 2023;30:287-297. doi: 10.1007/978-3-031-21054-9_12. Adv Neurobiol. 2023. PMID: 36928855
- The impact of age on antidepressant response: A mega-analysis of individuals with major depressive disorder.Strawn JR, Mills JA, Suresh V, Mayes T, Gentry MT, Trivedi M, Croarkin PE. Strawn JR, et al. J Psychiatr Res. 2023 Mar;159:266-273. doi: 10.1016/j.jpsychires.2023.01.043. Epub 2023 Jan 28. J Psychiatr Res. 2023. PMID: 36774767
- Inflammation-Related Functional and Structural Dysconnectivity as a Pathway to Psychopathology.Goldsmith DR, Bekhbat M, Mehta ND, Felger JC. Goldsmith DR, et al. Biol Psychiatry. 2023 Mar 1;93(5):405-418. doi: 10.1016/j.biopsych.2022.11.003. Epub 2022 Nov 9. Biol Psychiatry. 2023. PMID: 36725140 Review.
- Inflammation and Treatment-Resistant Depression from Clinical to Animal Study: A Possible Link?Almutabagani LF, Almanqour RA, Alsabhan JF, Alhossan AM, Alamin MA, Alrajeh HM, Alonazi AS, El-Malky AM, Alrasheed NM. Almutabagani LF, et al. Neurol Int. 2023 Jan 16;15(1):100-120. doi: 10.3390/neurolint15010009. Neurol Int. 2023. PMID: 36648973 Free PMC article.
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Adult
- Antidepressive Agents / therapeutic use*
- Bupropion / therapeutic use*
- C-Reactive Protein / metabolism*
- Citalopram / therapeutic use*
- Depressive Disorder / blood
- Depressive Disorder / drug therapy*
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Remission Induction
- Self Report
- Treatment Outcome
- Antidepressive Agents
- Bupropion
- Citalopram
- C-Reactive Protein
- ClinicalTrials.gov/NCT00590863
- Full Text Sources
- Other Literature Sources
- Medical
- Research Materials
- Miscellaneous
![Figure 3.. Early reduction in depression severity…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6080717/bin/nihms-850658-f0003.jpg)
![Figure 4.. Remission rates during acute-phase of…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6080717/bin/nihms-850658-f0004.jpg)
Source: PubMed